Daniela Soto, 25, lives in Los Angeles and was diagnosed with ulcerative colitis (UC) when she was just 21. If you don’t know ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

Biomerica (BMRA) announces that its food intolerance products for Crohn’s Disease and Ulcerative Colitis have achieved CE-marking under the ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...

A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...

Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.

For more than a decade, Michelle Hobson endured extreme fatigue, excruciating abdominal pain, and repeated hospital visits.

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...